Interim Financial Disclosure Statements

For the six months ended 30 June 2016

Interim Financial Disclosure Statements For the six months ended 30 June 2016

| Contents | Pages |
|--|--------|
| General information and explanatory statement | 1 |
| Unaudited statement of comprehensive income | 2 |
| Unaudited balance sheet | 3 |
| Unaudited statement of changes in equity | 4 |
| Notes to the unaudited interim financial disclosure statements | 5 – 24 |

General Information and Explanatory Statement For the six months ended 30 June 2016

The directors announce the unaudited interim financial disclosure statements (the "disclosure statements") of Goldman Sachs Asia Bank Limited (the "Company"), a restricted licence bank, for the six months ended 30 June 2016. The disclosure statements are prepared in accordance with the Banking (Disclosure) Rules pursuant to Section 60A of the Hong Kong Banking Ordinance.

Principal activity

The Company is a limited liability company incorporated in Hong Kong on 12 December 2012. The address of its registered office is 68th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

The Company is a restricted licence bank under the Hong Kong Banking Ordinance. The Company has also been registered as a registered institution under the Hong Kong Securities and Futures Ordinance with effect from 29 July 2016.

The Company commenced business on 19 August 2016.

The Company's activities and results during the interim reporting period

The unaudited loss for the six months ended 30 June 2016 was US\$223,184, representing a decrease of 0.5% as compared to 30 June 2015. It was mainly contributed by operating expenses incurred.

Requirement in connection with publication of financial statements

The financial information relating to the year ended 31 December 2015 that is included in the unaudited interim financial disclosure statements for the six months ended 30 June 2016 as comparative information does not constitute the Company's statutory annual financial statements for the year ended 31 December 2015 but is derived from the audited financial statements for the year ended 31 December 2015. Further information relating to the audited financial statements for the year ended 31 December 2015 required to be disclosed in accordance with section 436 of the Companies Ordinance is as follows:

As the Company is a private company, the Company is not required to deliver its financial statements to the Registrar of Companies, and has not done so.

The Company's auditor has reported on the audited financial statements for the year ended 31 December 2015. The auditor's report was unqualified; did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying its report; and did not contain a statement under sections 406(2), 407(2) or (3) of the Companies Ordinance.

On behalf of the Board

Director 27 September 2016

Unaudited Statement of Comprehensive Income For the six months ended 30 June 2016

| | For the six months ended | | nonths ended |
|--|--------------------------|----------------------|----------------------|
| | Note | 30 June 2016 US\$ | 30 June 2015 US\$ |
| Interest income | 1 | 655 | 10 |
| Operating expenses | 2 | (223,839) | (224,371) |
| Loss before income tax | | (223,184) | (224,361) |
| Income tax expense | 3 | - | - |
| | | | |
| Loss and total comprehensive loss for the period | | (223,184) | (224,361) |

Unaudited Balance Sheet As at 30 June 2016

.

| | Note | 30 June 2016 US\$ | 31 December 2015 US\$ |
|--|------|-------------------------|-----------------------------|
| Assets | | | |
| Current assets | | | |
| Cash and balances with banks | 4 | 13,808,074 | 13,808,190 |
| Total assets | | 13,808,074 | 13,808,190 |
| Liabilities | | | |
| Current liabilities | | | |
| Amount due to related parties | | 629,817 | 205,468 |
| Other liabilities and accrued expenses | | 253,477 | 454,758 |
| Total liabilities | | 883,294 | 660,226 |
| Equity | | | |
| Share capital | | 14,010,000 | 14,010,000 |
| Accumulated losses | | (1,085,220) | (862,036) |
| Total equity | | 12,924,780 | 13,147,964 |
| Total equity and liabilities | | 13,808,074 | 13,808,190 |

Unaudited Statement of Changes in Equity For the six months ended 30 June 2016

| | Share capital US\$ | Accumulated losses US\$ | Total US\$ |
|---|-----------------------|-------------------------------|---------------|
| <u>2016</u> | • | • | • |
| Balance as at 1 January 2016 | 14,010,000 | (862,036) | 13,147,964 |
| Total comprehensive loss for the period | - | (223,184) | (223,184) |
| Balance as at 30 June 2016 | 14,010,000 | (1,085,220) | 12,924,780 |
| <u>2015</u> | | | |
| Balance as at 1 January 2015 | 10,000 | (420) | 9,580 |
| Additional capital contributions | 14,000,000 | - | 14,000,000 |
| Total comprehensive loss for the year | - | (861,616) | (861,616) |
| Balance as at 31 December 2015 | 14,010,000 | (862,036) | 13,147,964 |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

1 Interest income

Interest income recognized using the effective interest method is set out below:

| | For the six months ended | |
|--|--------------------------|--------------|
| | 30 June 2016 | 30 June 2015 |
| | US\$ | US\$ |
| Interest income from: | | |
| balances with financial institutions | 655 | 10 |
| | | |

2 Operating expenses

Operating expenses include:

| | For the six months ended | |
|--------------------------------------|--------------------------|--------------|
| | 30 June 2016 | 30 June 2015 |
| | US\$ | US\$ |
| Net currency translation (gain)/loss | (980) | 91 |
| Professional fees | 61,293 | 122,000 |
| Auditor's remuneration | 6,750 | 5,000 |
| Licenses and registration fees | 52,822 | - |
| Directors' emoluments | 100,000 | 97,222 |
| Other expenses | 3,954 | 58 |
| | 223,839 | 224,371 |

3 Income tax expense

No provision for Hong Kong profits tax has been made as the Company did not generate any assessable profits arising in Hong Kong during the six months ended 30 June 2016 (2015: Nil). All income either arises in, or is derived from Hong Kong, so no provision for overseas taxation is relevant.

Hong Kong profits tax for 2016 is calculated at 16.5% (2015: 16.5%) of the estimated assessable profit for the year.

4 Cash and balances with banks

| | 30 June | 31 December |
|---|------------|-------------|
| | 2016 | 2015 |
| | US\$ | US\$ |
| Cash and balances with financial institutions | 13,808,074 | 13,808,190 |

5 Deferred income tax

Deferred income tax assets are recognized for tax loss carry forward to the extent that the realization of the related tax benefit through future taxable profit is probable. The Company did not recognize deferred income tax asset of US\$49,042 (31 December 2015: US\$32,542) in respect of losses amounting to US\$297,222 (31 December 2015: US\$197,222) that can be carried forward against future taxable income.

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

6 Capital adequacy ratio

The capital ratios below are computed in accordance with the Banking (Capital) Rules of the Banking Ordinance.

| | 30 June 2016 | 31 December 2015 |
|---|-----------------|---------------------|
| Common Equity Tier 1 ("CET1") capital ratio | 246% | 274% |
| Tier 1 capital ratio | 246% | 274% |
| Total capital ratio | 246% | 274% |

The Company's capital conservation buffer ratio as at 30 June 2016 was 0.625% (31 December 2015: 0%) in accordance with Section 3M of the Banking (Capital) Rules.

Components of capital base

Total capital after deductions used in the calculation of capital adequacy ratio as at 30 June 2016 and 31 December 2015 are as follows:

| | 30 June 2016 US\$ | 31 December 2015 US\$ |
|---|-------------------------|------------------------------|
| CET1 capital instruments | | |
| Paid up ordinary share capital | 14,010,000 | 14,010,000 |
| Accumulated losses | (1,085,220) | (862,036) |
| CET1 capital before deductions Deductions CET1 capital after deductions | 12,924,780 | 13,147,964 13,147,964 |
| Additional Tier 1 capital | - · · · | - |
| Tier 2 capital | - | - |
| | 12 024 790 | 12 1 17 06 1 |
| Total capital | 12,924,780 | 13,147,964 |

Information relating to the disclosure of the full terms and conditions of the Company's capital instruments can be viewed on the website: <u>http://www.goldmansachs.com/disclosures/gsab-disclosures/terms-and-conditions.html</u>

7 Countercyclical capital buffer ("CCyB") ratio

The geographical breakdown of risk-weighted amounts ("RWA") in relation to private sector credit exposures as at 30 June 2016 is as follows:

| | | Applicable Jurisdictional CCyB ratio in | Total RWA used in computation of CCyB | | CCyB amount of |
|---|--------------|---|--|------------------|----------------|
| | Jurisdiction | effect | ratio of AI | CCyB ratio of AI | AI |
| 1 | Hong Kong | 0.625% | - | | |
| | Total | | - | - | - |

The Company's CCyB ratio was 0% as there was no private sector credit exposure as at 30 June 2016 and 31 December 2015.

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

8 Regulatory capital disclosures

(a) Transition Disclosures Template:

See Appendix 1 on pages 10 to 19.

(b) Balance sheet reconciliation between the Company's balance sheet and the capital components of regulatory capital:

See Appendix 2 on page 20.

(c) Main Features of Capital Instruments:

See Appendix 3 on page 21.

9 Leverage Ratio Disclosure Templates – Summary Comparison Table and Leverage Ratio Common Disclosure Template:

The leverage ratio as at 30 June 2016 and 31 December 2015 was compiled in accordance with Section 24A of the Banking (Disclosure) Rules.

See Appendix 4 on pages 22 to 24.

10 Liquidity risk management

Liquidity risk is the risk that the Company does not have sufficient cash or collateral to make payments to its counterparties and customers as they fall due. Liquidity is of critical importance to financial institutions. Most of the failures of financial institutions have occurred in large part due to insufficient liquidity. Accordingly, the Company has in place a comprehensive and conservative set of liquidity and funding policies to address both company-specific and broader industry or market liquidity events. The principal objective is to be able to fund the Company and to enable the core businesses to continue to serve clients and generate revenues, even under adverse circumstances.

The Company manages liquidity risk according to the following principles:

- liquidity maintaining substantial excess liquidity to meet a broad range of potential cash outflows and collateral needs in a stressed environment;
- asset / liability management assessing anticipated holding periods for the Company's assets and their expected liquidity in a stressed environment, maintaining the maturities and diversity of funding across markets, products and counterparties, and seeking to maintain liabilities of appropriate tenor relative to the asset base; and
- contingency funding plan maintaining a contingency funding plan to provide a framework for analysing and responding to a liquidity crisis situation or periods of market stress. The framework sets forth the plan of action to fund normal business activity in emergency and stressed situations.

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

11 Liquidity

| | For the six months ended 30 June 2016 |
|-------------------------------------|---|
| Average liquidity maintenance ratio | 160% |

The average liquidity maintenance ratio is computed in accordance with the Banking (Liquidity) Rules.

As at 30 June 2015, the Company was not a restricted licence bank under the Banking Ordinance and therefore was not required to maintain the liquidity maintenance ratio for the six months ended 30 June 2015. There is no applicable comparative information disclosed accordingly.

12 Currency risk

The currency risk arising from the Company's operations for those individual currencies which each constitute more than 10% of the total net positions in all foreign currencies are as follows:

30 June 2016

| <u></u> | CHF US\$ | GBP US\$ | USD US\$ |
|----------------------|-------------|-------------|--------------|
| Spot assets | 9,700 | 9,840 | 13,658,208 |
| Spot liabilities | - | - | (13,628,030) |
| Forward purchases | - | - | - |
| Forward sales | - | - | - |
| Net options position | - | - | - |
| Net long position | 9,700 | 9,840 | 30,178 |

31 December 2015

| | US\$ |
|----------------------|--------------|
| Spot assets | 13,806,673 |
| Spot liabilities | (13,686,464) |
| Forward purchases | - |
| Forward sales | - |
| Net options position | - |
| Net long position | 120,209 |

USD

As at 30 June 2016 and 31 December 2015, there was no foreign currency exposure arising from structural positions.

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

13 International claims

International claims are on-balance sheet exposures to counterparties based on the country of the counterparties after taking into account any risk transfer. The risk transfers have been made if the claims are on an overseas branch of a bank whose head office is located in another country.

30 June 2016

| | Banks | Total |
|--------------------------------------|---------------|---------------|
| | US\$ | US\$ |
| Developed countries | | |
| United Kingdom | 2,745,432 | 2,745,432 |
| United States | 5,451,296 | 5,451,296 |
| <u>31 December 2015</u> | Banks US\$ | Total US\$ |
| Developed countries United States | 6,798,673 | 6,798,673 |

14 Loans and advances – sector information

There are no loans and advances to customers as at 30 June 2016 and 31 December 2015.

15 Impaired, overdue and rescheduled assets

There are no impaired, overdue or rescheduled assets as at 30 June 2016 and 31 December 2015.

16 Mainland activities

There are no non-bank mainland exposures as at 30 June 2016 and 31 December 2015.

17 Derivative transactions and other off-balance sheet exposures

There are no derivative transactions or off-balance sheet exposures as at 30 June 2016 and 31 December 2015.

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 **Transition Disclosures Template**

The following tables set out the detailed composition of the Company's regulatory capital as at 30 June 2016 and 31 December 2015 using the Transition Disclosures Template as specified by the HKMA. The tables also show those items that are currently benefiting from the Basel III transitional arrangements, and are consequently subject to the pre-Basel III treatment, as set out in Schedule 4H to the Banking (Capital) Rules.

30 June 2016

| <u>30 Jur</u> | <u>e 2016</u> | | , | |
|---------------|---|-------------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| | CET1 capital: instruments and reserves | | | |
| 1 | Directly issued qualifying CET1 capital instruments plus any related share premium | 14,010,000 | | (1) |
| 2 | Retained earnings | (1,085,220) | | (2) |
| 3 | Disclosed reserves | - | | |
| 4 | Directly issued capital subject to phase out from CET1 capital (only applicable to non-joint stock companies) | Not applicable | | |
| | Public sector capital injections grandfathered until 1 January 2018 | Not applicable | | |
| 5 | Minority interests arising from CET1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in CET1 capital of the consolidation group) | - | | |
| 6 | CET1 capital before regulatory deductions | 12,924,780 | | |
| | CET1 capital: regulatory deductions | | | |
| 7 | Valuation adjustments | - | | |
| 8 | Goodwill (net of associated deferred tax liability) | - | | |
| 9# | Other intangible assets (net of associated deferred tax liability) | - | - | |
| 10# | Deferred tax assets net of deferred tax liabilities | - | | |
| 11 | Cash flow hedge reserve | - | | |
| 12 | Excess of total EL amount over total eligible provisions under the IRB approach | - | | |
| 13 | Gain-on-sale arising from securitization transactions | - | | |
| 14 | Gains and losses due to changes in own credit risk on fair valued liabilities | - | - | |
| 15 | Defined benefit pension fund net assets (net of associated deferred tax liabilities) | - | - | |
| 16 | Investments in own CET1 capital instruments (if not already netted off paid-in capital on reported balance sheet) | - | - | |
| 17 | Reciprocal cross-holdings in CET1 capital instruments | - | | |
| 18# | Insignificant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | - | |
| 19# | Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | - | |
| 20 | Mortgage servicing rights (amount above 10% threshold) | Not applicable | | |
| 21 | Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related tax liability) | Not applicable | | |
| 22 | Amount exceeding the 15% threshold | Not applicable | | |
| 23 | of which: significant investments in the common stock of financial sector entities | Not applicable | | |
| 24 | of which: mortgage servicing rights | Not applicable | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 Transition Disclosures Template (continued)

<u>30 June 2016</u>

| <u>30 Jur</u> | <u>le 2016</u> | | | |
|---------------|--|----------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| | CET1 capital: regulatory deductions | | | |
| 25 | of which: deferred tax assets arising from temporary differences | Not applicable | | |
| 26 | National specific regulatory adjustments applied to CET1 capital | - | | |
| 26a | Cumulative fair value gains arising from the revaluation of land and buildings (own-use and investment properties) | - | | |
| 26b | Regulatory reserve for general banking risks | - | | |
| 26c | Securitization exposures specified in a notice given by the Monetary Authority | - | | |
| 26d | Cumulative losses below depreciated cost arising from the institution's holdings of land and buildings | - | | |
| 26e | Capital shortfall of regulated non-bank subsidiaries | - | | |
| 26f | Capital investment in a connected company which is a commercial entity (amount above 15% of the reporting institution's capital base) | - | - | |
| 27 | Regulatory deductions applied to CET1 capital due to insufficient AT1 capital and Tier 2 capital to cover deductions | - | | |
| 28 | Total regulatory deductions to CET1 capital | - | | |
| 29 | CET1 capital | 12,924,780 | | |
| | AT1 capital: instruments | | | |
| 30 | Qualifying AT1 capital instruments plus any related share premium | - | | |
| 31 | of which: classified as equity under applicable accounting standards | - | | |
| 32 | of which: classified as liabilities under applicable accounting standards | - | | |
| 33 | Capital instruments subject to phase out arrangements from AT1 capital | - | | |
| 34 | AT1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in AT1 capital of the consolidation group) | - | | |
| 35 | of which: AT1 capital instruments issued by subsidiaries subject to phase out arrangements | - | | |
| 36 | AT1 capital before regulatory deductions | - | | |
| | AT1 capital: regulatory deductions | | | |
| 37 | Investments in own AT1 capital instruments | - | - | |
| 38 | Reciprocal cross-holdings in AT1 capital instruments | - | | |
| 39# | Insignificant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | - | |
| 40 | Significant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | - | |
| 41 | National specific regulatory adjustments applied to AT1 capital | - | | |
| 41a | Portion of deductions applied 50:50 to core capital and supplementary capital based on pre-Basel III treatment which, during transitional period, remain subject to deduction from Tier 1 capital | - | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 Transition Disclosures Template (continued)

<u>30 June 2016</u>

| <u>30 Jur</u> | <u>e 2016</u> | | | |
|---------------|---|------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | reconciliation |
| | AT1 capital: regulatory deductions | + | | |
| i | of which: Excess of total EL amount over total eligible provisions under the IRB approach | - | | |
| ii | of which: Capital shortfall of regulated non-bank subsidiaries | - | | |
| iii | of which: Investments in own CET1 capital instruments | - | | |
| iv | of which: Reciprocal cross holdings in CET1 capital instruments issued by financial sector entities | - | | |
| v | of which: Capital investment in a connected company which is a commercial entity (amount above 15% of the reporting institution's capital base) | - | | |
| vi | of which: Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| vii | of which: Significant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 42 | Regulatory deductions applied to AT1 capital due to insufficient Tier 2 capital to cover deductions | - | | |
| 43 | Total regulatory deductions to AT1 capital | - | | |
| 44 | AT1 capital | - | | |
| 45 | Tier 1 capital (Tier 1 = CET1 + AT1) | 12,924,780 | | |
| | Tier 2 capital: instruments and provisions | | | |
| 46 | Qualifying Tier 2 capital instruments plus any related share premium | - | | |
| 47 | Capital instruments subject to phase out arrangements from Tier 2 capital | - | | |
| 48 | Tier 2 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in Tier 2 capital of the consolidation group) | - | | |
| 49 | of which: capital instruments issued by subsidiaries subject to phase out arrangements | - | | |
| 50 | Collective impairment allowances and regulatory reserve for general banking risks eligible for inclusion in Tier 2 capital | - | | |
| 51 | Tier 2 capital before regulatory deductions | - | | |
| | Tier 2 capital: regulatory deductions | | | |
| 52 | Investments in own Tier 2 capital instruments | - | - | |
| 53 | Reciprocal cross-holdings in Tier 2 capital instruments | - | | |
| 54# | Insignificant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | | |
| 55 | Significant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 56 | National specific regulatory adjustments applied to Tier 2 capital | - | | |
| 56a | Add back of cumulative fair value gains arising from the revaluation of land and buildings (own-use and investment properties) eligible for inclusion in Tier 2 capital | - | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 Transition Disclosures Template (continued)

<u>30 June 2016</u>

| <u>30 Jun</u> | <u>e 2016</u> | | | |
|---------------|---|------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| | Tier 2 capital: regulatory deductions | | | |
| 56b | Portion of deductions applied 50:50 to core capital and supplementary capital based on pre-Basel III treatment which, during transitional period, remain subject to deduction from Tier 2 capital | - | | |
| i | of which: Excess of total EL amount over total eligible provisions under the IRB approach | - | | |
| ii | of which: Capital shortfall of regulated non-bank subsidiaries | - | | |
| iii | of which: Investments in own CET1 capital instruments | - | | |
| iv | of which: Reciprocal cross holdings in CET1 capital instruments issued by financial sector entities | - | | |
| v | of which: Capital investment in a connected company which is a commercial entity (amount above 15% of the reporting institution's capital base) | - | | |
| vi | of which: Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| vii | of which: Significant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 57 | Total regulatory deductions to Tier 2 capital | - | | |
| 58 | Tier 2 capital | - | | |
| 59 | Total capital (Total capital = Tier 1 + Tier 2) | 12,924,780 | | |
| 59a | Deduction items under Basel III which during transitional period remain subject to risk-weighting, based on pre-Basel III treatment | | | |
| i | of which: Mortgage servicing rights | - | | |
| ii | of which: Defined benefit pension fund net assets | - | | |
| iii | of which: Investments in own CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments | | | |
| iv | of which: Capital investment in a connected company which is a commercial entity | - | | |
| v | of which: Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| vi | of which: Significant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 60 | Total risk weighted assets | 5,262,640 | | |
| | Capital ratios (as a percentage of risk weighted assets) | | | |
| 61 | CET1 capital ratio | 245.6% | | |
| 62 | Tier 1 capital ratio | 245.6% | | |
| 63 | Total capital ratio | 245.6% | | |
| 64 | Institution specific buffer requirement (minimum CET1 capital requirement as specified in s.3A, or s.3B, as the case requires, of the BCR plus capital conservation buffer plus countercyclical buffer requirements plus G-SIB or D-SIB requirements) | 5.125% | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 **Transition Disclosures Template (continued)**

| <u>30 Ju</u> | <u>ne 2016</u> | | | |
|--------------|--|-------------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| 65 | of which: capital conservation buffer requirement | 0.625% | | |
| 66 | of which: bank specific countercyclical buffer requirement | 0% | | |
| 67 | of which: G-SIB or D-SIB buffer requirement | 0% | | |
| 68 | CET1 capital surplus over the minimum CET1 requirement and any CET1 capital used to meet the Tier 1 and Total capital requirement under s.3A, or s.3B, as the case requires, of the BCR | 241.1% | | |
| | National minima (if different from Basel 3 minimum) | | | |
| 69 | National CET1 minimum ratio | Not | | |
| | | applicable Not | | |
| 70 | National Tier 1 minimum ratio | applicable | | |
| 71 | National Total capital minimum ratio | Not | | |
| / 1 | | applicable | | |
| | Amounts below the thresholds for deduction (before risk weigh | iting) | | |
| 72 | Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 73 | Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 74 | Mortgage servicing rights (net of related tax liability) | Not applicable | | |
| 75 | Deferred tax assets arising from temporary differences (net of related tax liability) | Not applicable | | |
| | Applicable caps on the inclusion of provisions in Tier 2 capit | al | | |
| 76 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the basic approach and the standardized (credit risk) approach (prior to application of cap) | - | | |
| 77 | Cap on inclusion of provisions in Tier 2 under the basic approach and the standardized (credit risk) approach | - | | |
| 78 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the IRB approach (prior to application of cap) | - | | |
| 79 | Cap for inclusion of provisions in Tier 2 under the IRB approach | - | | |
| | Capital instruments subject to phase-out arrangements | | | |
| 80 | Current cap on CET1 capital instruments subject to phase out arrangements | Not applicable | | |
| 81 | Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities) | Not applicable | | |
| 82 | Current cap on AT1 capital instruments subject to phase out arrangements | - | | |
| 83 | Amount excluded from AT1 capital due to cap (excess over cap after redemptions and maturities) | - | | |
| 84 | Current cap on Tier 2 capital instruments subject to phase out arrangements | - | | |
| 85 | Amount excluded from Tier 2 capital due to cap (excess over cap after redemptions and maturities) | - | | |

* This refers to the position under the Banking (Capital) Rules in force on 31 December 2012.

Footnote: [#] Indicates elements where a more conservative definition has been applied in the BCR relative to that set out in the Basel III capital standards. Abbreviations: CET1: Common Equity Tier 1

AT1: Additional Tier 1

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 Transition Disclosures Template (continued)

| 31 Dec | cember 2015 | | | 0 |
|--------|---|-------------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| | CET1 capital: instruments and reserves | - | | |
| 1 | Directly issued qualifying CET1 capital instruments plus any related share premium | 14,010,000 | | (1) |
| 2 | Retained earnings | (862,036) | | (2) |
| 3 | Disclosed reserves | - | | |
| 4 | Directly issued capital subject to phase out from CET1 capital (only applicable to non-joint stock companies) | Not applicable | | |
| | Public sector capital injections grandfathered until 1 January 2018 | Not applicable | | |
| 5 | Minority interests arising from CET1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in CET1 capital of the consolidation group) | - | | |
| 6 | CET1 capital before regulatory deductions | 13,147,964 | | |
| | CET1 capital: regulatory deductions | | | |
| 7 | Valuation adjustments | - | | |
| 8 | Goodwill (net of associated deferred tax liability) | - | | |
| 9# | Other intangible assets (net of associated deferred tax liability) | - | - | |
| 10# | Deferred tax assets net of deferred tax liabilities | - | | |
| 11 | Cash flow hedge reserve | - | | |
| 12 | Excess of total EL amount over total eligible provisions under the IRB approach | - | - | |
| 13 | Gain-on-sale arising from securitization transactions | - | | |
| 14 | Gains and losses due to changes in own credit risk on fair valued liabilities | - | - | |
| 15 | Defined benefit pension fund net assets (net of associated deferred tax liabilities) | - | - | |
| 16 | Investments in own CET1 capital instruments (if not already netted off paid-in capital on reported balance sheet) | - | - | |
| 17 | Reciprocal cross-holdings in CET1 capital instruments | - | - | |
| 18# | Insignificant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | - | |
| 19# | Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | - | |
| 20 | Mortgage servicing rights (amount above 10% threshold) | Not applicable | | |
| 21 | Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related tax liability) | Not applicable | | |
| 22 | Amount exceeding the 15% threshold | Not applicable | | |
| 23 | of which: significant investments in the common stock of financial sector entities | Not applicable | | |
| 24 | of which: mortgage servicing rights | Not applicable | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 Transition Disclosures Template (continued)

| <u>31 Dec</u> | cember 2015 | | | |
|---------------|--|----------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| | CET1 capital: regulatory deductions | | | |
| 25 | of which: deferred tax assets arising from temporary differences | Not applicable | | |
| 26 | National specific regulatory adjustments applied to CET1 capital | - | | |
| 26a | Cumulative fair value gains arising from the revaluation of land and buildings (own-use and investment properties) | - | | |
| 26b | Regulatory reserve for general banking risks | - | | |
| 26c | Securitization exposures specified in a notice given by the Monetary Authority | - | | |
| 26d | Cumulative losses below depreciated cost arising from the institution's holdings of land and buildings | - | | |
| 26e | Capital shortfall of regulated non-bank subsidiaries | - | - | |
| 26f | Capital investment in a connected company which is a commercial entity (amount above 15% of the reporting institution's capital base) | - | - | |
| 27 | Regulatory deductions applied to CET1 capital due to insufficient AT1 capital and Tier 2 capital to cover deductions | - | | |
| 28 | Total regulatory deductions to CET1 capital | - | | |
| 29 | CET1 capital | 13,147,964 | | |
| | AT1 capital: instruments | | | |
| 30 | Qualifying AT1 capital instruments plus any related share premium | - | | |
| 31 | of which: classified as equity under applicable accounting standards | - | | |
| 32 | of which: classified as liabilities under applicable accounting standards | - | | |
| 33 | Capital instruments subject to phase out arrangements from AT1 capital | - | | |
| 34 | AT1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in AT1 capital of the consolidation group) | - | | |
| 35 | of which: AT1 capital instruments issued by subsidiaries subject to phase out arrangements | - | | |
| 36 | AT1 capital before regulatory deductions | - | | |
| | AT1 capital: regulatory deductions | | | |
| 37 | Investments in own AT1 capital instruments | - | - | |
| 38 | Reciprocal cross-holdings in AT1 capital instruments | - | - | |
| 39# | Insignificant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | - | |
| 40 | Significant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | - | |
| 41 | National specific regulatory adjustments applied to AT1 capital | - | | |
| 41a | Portion of deductions applied 50:50 to core capital and supplementary capital based on pre-Basel III treatment which, during transitional period, remain subject to deduction from Tier 1 capital | - | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 Transition Disclosures Template (continued)

| <u>31 De</u> | cember 2015 | | Amounts subject to | Cross reference to |
|--------------|---|------------|-----------------------------|------------------------------------|
| | | | pre-Basel III treatment* | balance sheet reconciliation |
| | | US\$ | US\$ | |
| | AT1 capital: regulatory deductions | | | |
| i | of which: Excess of total EL amount over total eligible provisions under the IRB approach | - | | |
| ii | of which: Capital shortfall of regulated non-bank subsidiaries | - | | |
| iii | of which: Investments in own CET1 capital instruments | - | | |
| iv | of which: Reciprocal cross holdings in CET1 capital instruments issued by financial sector entities | - | | |
| v | of which: Capital investment in a connected company which is a commercial entity (amount above 15% of the reporting institution's capital base) | - | | |
| vi | of which: Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| vii | of which: Significant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 42 | Regulatory deductions applied to AT1 capital due to insufficient Tier 2 capital to cover deductions | - | | |
| 43 | Total regulatory deductions to AT1 capital | - | | |
| 44 | AT1 capital | - | | |
| 45 | Tier 1 capital (Tier 1 = CET1 + AT1) | 13,147,964 | | |
| | Tier 2 capital: instruments and provisions | | | |
| 46 | Qualifying Tier 2 capital instruments plus any related share premium | - | | |
| 47 | Capital instruments subject to phase out arrangements from Tier 2 capital | - | | |
| 48 | Tier 2 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in Tier 2 capital of the consolidation group) | - | | |
| 49 | of which: capital instruments issued by subsidiaries subject to phase out arrangements | - | | |
| 50 | Collective impairment allowances and regulatory reserve for general banking risks eligible for inclusion in Tier 2 capital | - | | |
| 51 | Tier 2 capital before regulatory deductions | - | | |
| | Tier 2 capital: regulatory deductions | | | |
| 52 | Investments in own Tier 2 capital instruments | - | - | |
| 53 | Reciprocal cross-holdings in Tier 2 capital instruments | - | | |
| 54# | Insignificant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold) | - | - | |
| 55 | Significant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | - | |
| 56 | National specific regulatory adjustments applied to Tier 2 capital | - | | |
| 56a | Add back of cumulative fair value gains arising from the revaluation of land and buildings (own-use and investment properties) eligible for inclusion in Tier 2 capital | - | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 Transition Disclosures Template (continued)

| <u>31 Dec</u> | cember 2015 | | | r |
|---------------|--|------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| | Tier 2 capital: regulatory deductions | | | |
| 56b | Portion of deductions applied 50:50 to core capital and supplementary capital based on pre-Basel III treatment which, during transitional period, remain subject to deduction from Tier 2 capital | - | | |
| i | of which: Excess of total EL amount over total eligible provisions under the IRB approach | - | | |
| ii | of which: Capital shortfall of regulated non-bank subsidiaries | - | | |
| iii | of which: Investments in own CET1 capital instruments | - | | |
| iv | of which: Reciprocal cross holdings in CET1 capital instruments issued by financial sector entities | - | | |
| v | of which: Capital investment in a connected company which is a commercial entity (amount above 15% of the reporting institution's capital base) | - | | |
| vi | of which: Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| vii | of which: Significant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 57 | Total regulatory deductions to Tier 2 capital | - | | |
| 58 | Tier 2 capital | - | | |
| 59 | Total capital (Total capital = Tier 1 + Tier 2) | 13,147,964 | | |
| 59a | Deduction items under Basel III which during transitional period remain subject to risk-weighting, based on pre-Basel III treatment | | | |
| i | of which: Mortgage servicing rights | - | | |
| ii | of which: Defined benefit pension fund net assets | - | | |
| iii | of which: Investments in own CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments | | | |
| iv | of which: Capital investment in a connected company which is a commercial entity | - | | |
| v | of which: Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| vi | of which: Significant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 60 | Total risk weighted assets | 4,803,869 | | |
| | Capital ratios (as a percentage of risk weighted assets) | | | |
| 61 | CET1 capital ratio | 273.7% | | |
| 62 | Tier 1 capital ratio | 273.7% | | |
| 63 | Total capital ratio | 273.7% | | |
| 64 | Institution specific buffer requirement (minimum CET1 capital requirement as specified in s.3A, or s.3B, as the case requires, of the BCR plus capital conservation buffer plus countercyclical buffer requirements plus G-SIB or D-SIB requirements) [^] | 4.5% | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 1 **Transition Disclosures Template (continued)**

| <u>31 De</u> | ecember 2015 | | | |
|--------------|--|-------------------|--|---|
| | | | Amounts subject to pre-Basel III treatment* | Cross reference to balance sheet reconciliation |
| | | US\$ | US\$ | |
| 65 | of which: capital conservation buffer requirement | 0% | | |
| 66 | of which: bank specific countercyclical buffer requirement | 0% | | |
| 67 | of which: G-SIB or D-SIB buffer requirement | 0% | | |
| 68 | CET1 capital surplus over the minimum CET1 requirement and any CET1 capital used to meet the Tier 1 and Total capital requirement under s.3A, or s.3B, as the case requires, of the BCR [^] | 269.2% | | |
| | National minima (if different from Basel 3 minimum) | | | |
| 69 | National CET1 minimum ratio | Not | | |
| | | applicable Not | | |
| 70 | National Tier 1 minimum ratio | applicable | | |
| 71 | National Total capital minimum ratio | Not | | |
| / 1 | | applicable | | |
| | Amounts below the thresholds for deduction (before risk weigh | iting) | | |
| 72 | Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 73 | Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | - | | |
| 74 | Mortgage servicing rights (net of related tax liability) | Not applicable | | |
| 75 | Deferred tax assets arising from temporary differences (net of related tax liability) | Not applicable | | |
| | Applicable caps on the inclusion of provisions in Tier 2 capit | tal | | |
| 76 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the basic approach and the standardized (credit risk) approach (prior to application of cap) | - | | |
| 77 | Cap on inclusion of provisions in Tier 2 under the basic approach and the standardized (credit risk) approach | - | | |
| 78 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the IRB approach (prior to application of cap) | - | | |
| 79 | Cap for inclusion of provisions in Tier 2 under the IRB approach | - | | |
| | Capital instruments subject to phase-out arrangements | | | |
| 80 | Current cap on CET1 capital instruments subject to phase out arrangements | Not applicable | | |
| 81 | Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities) | Not applicable | | |
| 82 | Current cap on AT1 capital instruments subject to phase out arrangements | - | | |
| 83 | Amount excluded from AT1 capital due to cap (excess over cap after redemptions and maturities) | - | | |
| 84 | Current cap on Tier 2 capital instruments subject to phase out arrangements | - | | |
| 85 | Amount excluded from Tier 2 capital due to cap (excess over cap after redemptions and maturities) | - | | |

* This refers to the position under the Banking (Capital) Rules in force on 31 December 2012.

Footnote: [#] Indicates elements where a more conservative definition has been applied in the BCR relative to that set out in the Basel III capital standards. ^ The comparatives have been restated to conform with the current period's presentation. <u>Abbreviations:</u> CET1: Common Equity Tier 1 AT1: Additional Tier 1

AT1: Additional Tier 1

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 2 Balance Sheet Reconciliation

The following tables show a reconciliation of amounts shown in the balance sheet of the Company to the capital components of regulatory capital:

30 June 2016

| | Balance Sheet as in Published Financial Statements | Under regulatory scope of consolidation | Cross reference to Transition Disclosure Template |
|--|--|---|---|
| | US\$ | US\$ | |
| Assets | | | |
| Cash and balances with banks | 13,808,074 | 13,808,074 | |
| Total Assets | 13,808,074 | 13,808,074 | |
| Liabilities | | | |
| Amount due to related parties | 629,817 | 629,817 | |
| Other liabilities and accrued expenses | 253,477 | 253,477 | |
| Total Liabilities | 883,294 | 883,294 | |
| Equity | | | |
| Share capital | 14,010,000 | 14,010,000 | (1) |
| Accumulated losses | (1,085,220) | (1,085,220) | (2) |
| Total Equity | 12,924,780 | 12,924,780 | |
| Total Liabilities and Equity | 13,808,074 | 13,808,074 | |

| | Balance Sheet as in Published Financial Statements | Under regulatory scope of consolidation | Cross reference to Transition Disclosure Template |
|--|--|---|---|
| | US\$ | US\$ | |
| Assets | | | |
| Cash and balances with banks | 13,808,190 | 13,808,190 | |
| Total Assets | 13,808,190 | 13,808,190 | |
| Liabilities | | | |
| Amount due to related parties | 205,468 | 205,468 | |
| Other liabilities and accrued expenses | 454,758 | 454,758 | |
| Total Liabilities | 660,226 | 660,226 | |
| Equity | | | |
| Share capital | 14,010,000 | 14,010,000 | (1) |
| Accumulated losses | (862,036) | (862,036) | (2) |
| Total Equity | 13,147,964 | 13,147,964 | |
| Total Liabilities and Equity | 13,808,190 | 13,808,190 | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 3 **Main Features of Capital Instruments**

The following table shows the main features of outstanding capital instruments as at 30 June 2016 and 31 December 2015:

| Dece | mber 2015: | |
|------|---|--|
| 1 | Issuer | Goldman Sachs Asia Bank Limited (formerly known as Goldman Sachs Asia Pacific Company Limited) |
| 2 | Unique identifier (eg CUSIP, ISIN or Bloomberg identifier for private placement) | Not applicable |
| 3 | Governing law(s) of the instrument | Hong Kong Law |
| | Regulatory treatment | |
| 4 | Transitional Basel III rules [#] | Not applicable |
| 5 | Post-transitional Basel III rules ⁺ | Common Equity Tier 1 |
| 6 | Eligible at solo*/group/group & solo | Solo |
| 7 | Instrument type (types to be specified by each jurisdiction) | Ordinary Shares |
| 8 | Amount recognised in regulatory capital (Currency in million, as of most recent reporting date) [^] | US\$14.01 million |
| 9 | Par value of instrument | Not applicable |
| 10 | Accounting classification | Shareholders' equity |
| 11 | Original date of issuance | 10,000 shares issued on 12 December 2012 1,000,000 shares issued on 14 January 2015 13,000,000 shares issued on 26 June 2015 |
| 12 | Perpetual or dated | Perpetual |
| 13 | Original maturity date | No maturity |
| 14 | Issuer call subject to prior supervisory approval | No |
| 15 | Optional call date, contingent call dates and redemption amount | Not applicable |
| 16 | Subsequent call dates, if applicable | Not applicable |
| | Coupons / dividends | |
| 17 | Fixed or floating dividend/coupon | Floating |
| 18 | Coupon rate and any related index | Not applicable |
| 19 | Existence of a dividend stopper | No |
| 20 | Fully discretionary, partially discretionary or mandatory | Fully discretionary |
| 21 | Existence of step up or other incentive to redeem | No |
| 22 | Noncumulative or cumulative | Noncumulative |
| 23 | Convertible or non-convertible | Non-convertible |
| 24 | If convertible, conversion trigger (s) | Not applicable |
| 25 | If convertible, fully or partially | Not applicable |
| 26 | If convertible, conversion rate | Not applicable |
| 27 | If convertible, mandatory or optional conversion | Not applicable |
| 28 | If convertible, specify instrument type convertible into | Not applicable |
| 29 | If convertible, specify issuer of instrument it converts into | Not applicable |
| 30 | Write-down feature | No |
| 31 | If write-down, write-down trigger(s) | Not applicable |
| 32 | If write-down, full or partial | Not applicable |
| 33 | If write-down, permanent or temporary | Not applicable |
| 34 | If temporary write-down, description of write-up mechanism | Not applicable |
| 35 | Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument) | Not applicable |
| 36 | Non-compliant transitioned features | No |
| 37 | If yes, specify non-compliant features | Not applicable |

Footnote:

[#] Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H of the Banking (Capital) Rules ⁺ Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H of the Banking (Capital) Rule

* Include solo-consolidated The comparative has been restated to conform with the current period's presentation.

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 4 Leverage Ratio Disclosure Templates

<u>30 June 2016</u>

Summary Comparison Table

| | Item | Leverage ratio framework US\$ equivalent |
|---|--|---|
| 1 | Total consolidated assets as per published financial statements | 13,808,074 |
| 2 | Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation | - |
| 3 | Adjustment for fiduciary assets recognised on the balance sheet pursuant to the operative accounting framework but excluded from the leverage ratio exposure measure | - |
| 4 | Adjustments for derivative financial instruments | - |
| 5 | Adjustment for securities financing transactions (i.e. repos and similar secured lending) | - |
| 6 | Adjustment for off-balance sheet items (i.e. conversion to credit equivalent amounts of off-balance sheet exposures) | - |
| 7 | Other adjustments | - |
| 8 | Leverage ratio exposure | 13,808,074 |

31 December 2015

Summary Comparison Table

| | Item | Leverage ratio framework US\$ equivalent |
|---|--|---|
| 1 | Total consolidated assets as per published financial statements | 13,808,190 |
| 2 | Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation | - |
| 3 | Adjustment for fiduciary assets recognised on the balance sheet pursuant to the operative accounting framework but excluded from the leverage ratio exposure measure | - |
| 4 | Adjustments for derivative financial instruments | - |
| 5 | Adjustment for securities financing transactions (i.e. repos and similar secured lending) | - |
| 6 | Adjustment for off-balance sheet items (i.e. conversion to credit equivalent amounts of off-balance sheet exposures) | - |
| 7 | Other adjustments | - |
| 8 | Leverage ratio exposure | 13,808,190 |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 4 Leverage Ratio Disclosure Templates (continued)

30 June 2016

Leverage Ratio Common Disclosure Template

| | Item | Leverage ratio framework US\$ equivalent |
|----|--|--|
| | On-balance sheet exposures | |
| 1 | On-balance sheet items (excluding derivatives and SFTs, but including collateral) | 13,808,074 |
| 2 | Less: Asset amounts deducted in determining Basel III Tier 1 capital (reported as negative amounts) | - |
| 3 | Total on-balance sheet exposures (excluding derivatives and SFTs) (sum of lines 1 and 2) | 13,808,074 |
| | Derivative exposures | |
| 4 | Replacement cost associated with all derivatives transactions (i.e. net of eligible cash variation margin) | - |
| 5 | Add-on amounts for PFE associated with all derivatives transactions | - |
| 6 | Gross-up for derivatives collateral provided where deducted from the balance sheet assets pursuant to the operative accounting framework | - |
| 7 | Less: Deductions of receivables assets for cash variation margin provided in derivatives transactions (reported as negative amounts) | - |
| 8 | Less: Exempted CCP leg of client-cleared trade exposures (reported as negative amounts) | - |
| 9 | Adjusted effective notional amount of written credit derivatives | - |
| 10 | Less: Adjusted effective notional offsets and add-on deductions for written credit derivatives (reported as negative amounts) | - |
| 11 | Total derivative exposures (sum of lines 4 to 10) | - |
| | Securities financing transaction exposures | |
| 12 | Gross SFT assets (with no recognition of netting), after adjusting for sales accounting transactions | - |
| 13 | Less: Netted amounts of cash payables and cash receivables of gross SFT assets (reported as negative amounts) | - |
| 14 | CCR exposure for SFT assets | - |
| 15 | Agent transaction exposures | - |
| 16 | Total securities financing transaction exposures (sum of lines 12 to 15) | - |
| | Other off-balance sheet exposures | |
| 17 | Off-balance sheet exposure at gross notional amount | - |
| 18 | Less: Adjustments for conversion to credit equivalent amounts (reported as negative amounts) | - |
| 19 | Off-balance sheet items (sum of lines 17 and 18) | - |
| | Capital and total exposures | |
| 20 | Tier 1 capital | 12,924,780 |
| 21 | Total exposures (sum of lines 3, 11, 16 and 19) | 13,808,074 |
| | Leverage ratio | |
| 22 | Basel III leverage ratio | 93.60% |
| | | |

Notes to the Unaudited Interim Financial Disclosure Statements For the six months ended 30 June 2016

Appendix 4 Leverage Ratio Disclosure Templates (continued)

31 December 2015

Leverage Ratio Common Disclosure Template

| | Item | Leverage ratio |
|----|--|------------------------------|
| | | framework US\$ equivalent |
| | On-balance sheet exposures | |
| 1 | On-balance sheet items (excluding derivatives and SFTs, but including collateral) | 13,808,190 |
| 2 | Less: Asset amounts deducted in determining Basel III Tier 1 capital (reported as negative amounts) | - |
| 3 | Total on-balance sheet exposures (excluding derivatives and SFTs) (sum of lines 1 and 2) | 13,808,190 |
| | Derivative exposures | |
| 4 | Replacement cost associated with all derivatives transactions (i.e. net of eligible cash variation margin) | - |
| 5 | Add-on amounts for PFE associated with all derivatives transactions | - |
| 6 | Gross-up for derivatives collateral provided where deducted from the balance sheet assets pursuant to the operative accounting framework | - |
| 7 | Less: Deductions of receivables assets for cash variation margin provided in derivatives transactions (reported as negative amounts) | - |
| 8 | Less: Exempted CCP leg of client-cleared trade exposures (reported as negative amounts) | - |
| 9 | Adjusted effective notional amount of written credit derivatives | - |
| 10 | Less: Adjusted effective notional offsets and add-on deductions for written credit derivatives (reported as negative amounts) | - |
| 11 | Total derivative exposures (sum of lines 4 to 10) | - |
| | Securities financing transaction exposures | |
| 12 | Gross SFT assets (with no recognition of netting), after adjusting for sales accounting transactions | - |
| 13 | Less: Netted amounts of cash payables and cash receivables of gross SFT assets (reported as negative amounts) | - |
| 14 | CCR exposure for SFT assets | - |
| 15 | Agent transaction exposures | - |
| 16 | Total securities financing transaction exposures (sum of lines 12 to 15) | - |
| | Other off-balance sheet exposures | |
| 17 | Off-balance sheet exposure at gross notional amount | - |
| 18 | Less: Adjustments for conversion to credit equivalent amounts (reported as negative amounts) | - |
| 19 | Off-balance sheet items (sum of lines 17 and 18) | - |
| | Capital and total exposures | |
| 20 | Tier 1 capital | 13,147,964 |
| 21 | Total exposures (sum of lines 3, 11, 16 and 19) | 13,808,190 |
| | Leverage ratio | |
| 22 | Basel III leverage ratio | 95.22% |